A Phase 2 interventional study of Tizanidine and Placebo in Spasticity, sponsored by Acorda Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.
Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Muscle Spasticity with a site in United States — 34 open to participants now, 44 under way, none of them phase 3. Muscle Spasticity · United States.
Among the 165 studies in Muscle Spasticity with a site in United States, this one is the 26th largest by enrollment of the 130 interventional ones that give a count, is one of 10 that started in 2013, is one of 18 in phase 2, and was the 60th registered.
622 studies on the registry are indexed under Muscle Spasticity; 128 are open to participants now.
Browse Muscle Spasticity studies →34 of the 165 studies in Muscle Spasticity with a site in United States are open now. Recruiting first, the newest first:
Kessler Foundation · Sites in United States
Ages 22+
Kessler Foundation · Sites in United States
Ages 18+
Alberto Esquenazi · Sites in United States
Ages 18–80
Martin Piazza · Sites in United States
Ages 3–14
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 29 · Phase 3 25 · Phase 4 9
First in 1997; this study’s year is marked. 10 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 36 across 473 interventional studies indexed under Muscle Spasticity.
Median enrollment 31 across the 130 interventional studies, 55 across the 34 observational. Of the 108 that completed or were terminated, 44 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 165 have an industry lead sponsor. The 10 most frequent:
Acorda Therapeutics is the lead sponsor of 38 studies on the registry; none are open to participants now.
Acorda Therapeutics has 4 studies filed under Muscle Spasticity — fewer than ten, so there is no comparison to draw.
17 of the studies in Muscle Spasticity with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07516067Martin PiazzaSpinal Cord Stimulation for Children With Cerebral Palsy | 2026-11 |
| NCT07792616University of Mississippi Medical CenterElectrical Neuromodulation for Modifying Spinal Network Involved in Spasticity | 2026-12-31 |
| NCT05094362Medical University of South CarolinaOperant Conditioning of Spinal Reflexes Training System--Reflex Operant Down Conditioning | 2026-12-31 |
| NCT06070233Ohio State UniversityRadiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy | 2026-12-31 |
| NCT06341023University of Illinois at ChicagoFunctional Balance Intervention in Multiple Sclerosis | 2027-01-09 |
Add all 17 to your calendar (.ics) → With an account.
Among the 165 studies in Muscle Spasticity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dose of 2 and 4 milligram (mg) tablets
Drug: Tizanidine
Placebo followed by a single dose 400 mg moxifloxacin tablets.
Drug: Placebo · Drug: Moxifloxacin
Single dose of 400 mg moxifloxacin followed by placebo.
Drug: Placebo · Drug: Moxifloxacin
Also known as: Zanaflex
The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.
Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.
Time frame: Baseline and Day 14
The Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.
Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.
Time frame: Baseline and Day 5
Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling
The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit.
Time frame: Day 5, Day 14
Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
Time frame: 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)
Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
Time frame: 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)
Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
Time frame: 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)
| Milestone | Tizanidine | Initial Placebo and Crossover to Moxifloxacin | Initial Moxifloxacin and Crossover to Placebo |
|---|---|---|---|
| Started | 72 | 32 | 32 |
| Qt/qtc analysis set | 72 | 32 | 32 |
| Pk analysis set | 70 | 0 | 0 |
| Moxifloxacin/placebo analysis set | 0 | 31 | 30 |
| Pk/qtc analysis set | 70 | 0 | 0 |
| Completed | 59 | 30 | 30 |
| Not completed | 13 | 2 | 2 |
| Withdrew: Adverse event | 4 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 | 1 |
| Withdrew: Classified as 'other' | 5 | 0 | 0 |
Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.
| milliseconds (msec) | Tizanidine 24 mg | Tizanidine Placebo 24 mg | Tizanidine 24 mg Placebo-corrected |
|---|---|---|---|
| Timepoint (Hour) 0 | -4.3 (-6.3 to -2.3) | -0.5 (-2.5 to 1.4) | -3.7 (-6.6 to -0.9) |
| 0.5 | -2.0 (-4.0 to 0.1) | 1.2 (-0.8 to 3.2) | -3.2 (-6.0 to -0.3) |
| 1 | -4.0 (-6.0 to -2.0) | 2.6 (0.6 to 4.5) | -6.6 (-9.4 to -3.8) |
| 1.5 | -4.7 (-6.9 to -2.6) | 2.7 (0.6 to 4.8) | -7.4 (-10.5 to -4.4) |
| 2 | -3.6 (-5.6 to -1.6) | 2.9 (0.9 to 4.8) | -6.4 (-9.2 to -3.6) |
| 4 | 1.6 (-0.4 to 3.6) | 3.4 (1.4 to 5.4) | -1.8 (-4.6 to 1.0) |
| 8 | -2.4 (-4.1 to -0.7) | 3.1 (1.4 to 4.8) | -5.5 (-7.9 to -3.1) |
| 12 | -2.0 (-3.5 to -0.5) | 1.0 (-0.5 to 2.5) | -3.0 (-5.1 to -0.8) |
| 24 | 0.4 (-1.3 to 2.2) | 2.6 (0.9 to 4.4) | -2.2 (-4.6 to 0.2) |
Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.
| msec | Tizanidine 8 mg | Tizanidine Placebo 8 mg | Tizanidine 8 mg Placebo-corrected |
|---|---|---|---|
| Timepoint (Hour) 0 | -0.8 (-2.5 to 0.8) | -0.9 (-2.7 to 0.8) | 0.1 (-2.3 to 2.5) |
| 0.5 | -0.4 (-2.3 to 1.4) | 0.4 (-1.5 to 2.3) | -0.8 (-3.5 to 1.8) |
| 1 | 0.0 (-1.9 to 1.9) | 2.3 (0.3 to 4.3) | -2.3 (-5.1 to 0.4) |
| 1.5 | 1.1 (-0.7 to 2.9) | 1.3 (-0.6 to 3.1) | -0.1 (-2.7 to 2.4) |
| 2 | -0.4 (-2.0 to 1.3) | 0.4 (-1.3 to 2.1) | -0.7 (-3.1 to 1.6) |
| 4 | 2.6 (1.2 to 4.0) | 1.0 (-0.5 to 2.5) | 1.6 (-0.4 to 3.6) |
| 8 | -1.5 (-3.1 to 0.0) | 0.6 (-1.0 to 2.3) | -2.2 (-4.4 to 0.1) |
| 12 | -0.1 (-1.6 to 1.4) | 0.7 (-0.9 to 2.3) | -0.8 (-3.0 to 1.5) |
| 24 | -0.5 (-2.0 to 1.0) | 1.4 (-0.1 to 3.0) | -1.9 (-4.1 to 0.3) |
The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit.
| msec per ng/mL | Tizanidine |
|---|---|
| Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling | -0.1209 (-0.1894 to -0.0524) |
| ng/mL | Day 5 (Tizanidine 8 mg) | Day 14 (Tizanidine 24 mg) |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State. | 11.7 ± 43.9 | 27.4 ± 42.7 |
| hour | Day 5 (Tizanidine 8 mg) | Day 14 (Tizanidine 24 mg) |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State. | 1.35 (0.600 to 4.10) | 2.10 (0.600 to 4.10) |
| ng*hr/mL | Day 5 (Tizanidine 8 mg) | Day 14 (Tizanidine 24 mg) |
|---|---|---|
| Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State. | 32.4 ± 65.1 | 115 ± 52.8 |
Collected over Up to 23 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tizanidine | — | 0/72 (0%) | 44/72 (61.1%) |
| Initial Placebo and Crossover to Moxifloxacin | — | 0/32 (0%) | 16/32 (50%) |
| Initial Moxifloxacin and Crossover to Placebo | — | 1/32 (3.1%) | 23/32 (71.9%) |
| Placebo and Moxifloxacin Groups Combined | — | 1/64 (1.6%) | 39/64 (60.9%) |
| Event | Tizanidine | Initial Placebo and Crossover to Moxifloxacin | Initial Moxifloxacin and Crossover to Placebo | Placebo and Moxifloxacin Groups Combined |
|---|---|---|---|---|
| Ectopic PregnancyPregnancy, puerperium and perinatal conditions | 0/72 | 0/32 | 1/32 | 1/64 |
| Event | Tizanidine | Initial Placebo and Crossover to Moxifloxacin | Initial Moxifloxacin and Crossover to Placebo | Placebo and Moxifloxacin Groups Combined |
|---|---|---|---|---|
| NERVOUS SYSTEM DISORDERSNervous system disorders | 32/72 | 8/32 | 8/32 | 16/64 |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONSGeneral disorders | 24/72 | 9/32 | 9/32 | 18/64 |
| GASTROINTESTINAL DISORDERSGastrointestinal disorders | 21/72 | 8/32 | 10/32 | 18/64 |
| SOMNOLENCENervous system disorders | 20/72 | 4/32 | 4/32 | 8/64 |
| DIZZINESSNervous system disorders | 17/72 | 2/32 | 4/32 | 6/64 |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERSSkin and subcutaneous tissue disorders | 8/72 | 4/32 | 7/32 | 11/64 |
| FATIGUEGeneral disorders | 13/72 | 1/32 | 1/32 | 2/64 |
| HEADACHENervous system disorders | 10/72 | 5/32 | 3/32 | 8/64 |
| NAUSEAGastrointestinal disorders | 9/72 | 4/32 | 5/32 | 9/64 |
| DRY MOUTHGastrointestinal disorders | 10/72 | 0/32 | 3/32 | 3/64 |
Safety Population
| Age, Continuous(years) | Tizanidine | Initial Placebo and Crossover to Moxifloxacin | Initial Moxifloxacin and Crossover to Placebo | Total |
|---|---|---|---|---|
| Mean | 33.4 ± 6.75 | 34.1 ± 7.51 | 35.3 ± 7.21 | 34.0 ± 7.03 |
| Sex: Female, Male(Participants) | Tizanidine | Initial Placebo and Crossover to Moxifloxacin | Initial Moxifloxacin and Crossover to Placebo | Total |
|---|---|---|---|---|
| Female | 39 | 17 | 17 | 73 |
| Male | 33 | 15 | 15 | 63 |
| Ethnicity (NIH/OMB)(Participants) | Tizanidine | Initial Placebo and Crossover to Moxifloxacin | Initial Moxifloxacin and Crossover to Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 30 | 6 | 12 | 48 |
| Not Hispanic or Latino | 42 | 26 | 20 | 88 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
The record gives a start of Apr 2013, a primary completion of Feb 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tizanidine